Literature DB >> 32591416

Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal: Time-Dependent Inhibition and Allosteric Effects.

Matthew G McDonald1, Dan-Dan Tian2, Kenneth E Thummel2, Mary F Paine2, Allan E Rettie2.   

Abstract

Botanical and other natural products (NPs) are often coconsumed with prescription medications, presenting a risk for cytochrome P450 (P450)-mediated NP-drug interactions. The NP goldenseal (Hydrastis canadensis) has exhibited antimicrobial activities in vitro attributed to isoquinoline alkaloids contained in the plant, primarily berberine, (-)-β-hydrastine, and to a lesser extent, hydrastinine. These alkaloids contain methylenedioxyphenyl rings, structural alerts with potential to inactivate P450s through formation of metabolic intermediate complexes. Time-dependent inhibition experiments were conducted to evaluate their ability to inhibit major P450 activities in human liver microsomes by using a cocktail of isozyme-specific substrate probes. Berberine inhibited CYP2D6 (dextromethorphan O-demethylation; K I = 2.7 μM, kinact = 0.065 minute-1) and CYP3A4/5 (midazolam 1'-hydroxylation; K I = 14.8 μM, kinact = 0.019 minute-1); (-)-β-hydrastine inhibited CYP2C9 (diclofenac 4'-hydroxylation; K I = 49 μM, kinact = 0.036 minute-1), CYP2D6 (K I > 250 μM, kinact > 0.06 minute-1), and CYP3A4/5 (K I = 28 μM, kinact = 0.056 minute-1); and hydrastinine inhibited CYP2D6 (K I = 37 μM, kinact = 0.049 minute-1) activity. Berberine additionally exhibited allosteric effects on midazolam hydroxylation, showing both positive and negative heterotropic cooperativity. Experiments with recombinant isozymes showed that berberine activated midazolam 1'-hydroxylation by CYP3A5, lowering K m(app), but showed mixed inhibition and negative cooperativity toward this reaction when catalyzed by CYP3A4. Berberine inactivated CYP3A4 at a much faster rate than CYP3A5 and was a noncompetitive inhibitor of midazolam 4-hydroxylation by CYP3A4 but a strong mixed inhibitor of the CYP3A5 catalyzed reaction. These complex kinetics should be considered when extrapolating the risk for NP-drug interactions involving goldenseal. SIGNIFICANCE STATEMENT: Robust kinetic parameters were determined for the reversible and time-dependent inhibition of CYP2C9, CYP2D6, and CYP3A4/5 activities in human liver microsomes by major component isoquinoline alkaloids contained in the botanical natural product goldenseal. The alkaloid berberine also exhibited opposing, isozyme-specific allosteric effects on midazolam hydroxylation mediated by recombinant CYP3A4 (inhibition) and CYP3A5 (activation). These data will inform the development of a physiologically based pharmacokinetic model that can be used to predict potential clinically relevant goldenseal-drug interactions.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2020        PMID: 32591416      PMCID: PMC7543482          DOI: 10.1124/dmd.120.091041

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes.

Authors:  Ping Zhao; Kent L Kunze; Caroline A Lee
Journal:  Drug Metab Dispos       Date:  2005-03-02       Impact factor: 3.922

2.  Allosteric Activation of Cytochrome P450 3A4 via Progesterone Bioconjugation.

Authors:  Vanja Polic; Karine Auclair
Journal:  Bioconjug Chem       Date:  2017-03-29       Impact factor: 4.774

3.  Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling.

Authors:  Sheng-Nan Lo; Yu-Ping Chang; Keng-Chang Tsai; Chia-Yu Chang; Tian-Shung Wu; Yune-Fang Ueng
Journal:  Toxicol Appl Pharmacol       Date:  2013-07-22       Impact factor: 4.219

4.  Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition.

Authors:  Keivan A Ettefagh; Johnna T Burns; Hiyas A Junio; Glenn W Kaatz; Nadja B Cech
Journal:  Planta Med       Date:  2010-12-14       Impact factor: 3.352

5.  Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.

Authors:  Dermot F McGinnity; Amanda J Berry; Jane R Kenny; Ken Grime; Robert J Riley
Journal:  Drug Metab Dispos       Date:  2006-05-05       Impact factor: 3.922

6.  Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.

Authors:  R Scott Obach; Robert L Walsky; Karthik Venkatakrishnan
Journal:  Drug Metab Dispos       Date:  2006-11-08       Impact factor: 3.922

7.  Effects of herbal products and their constituents on human cytochrome P450(2E1) activity.

Authors:  Gregory M Raner; Sean Cornelious; Kamalika Moulick; Yingqing Wang; Ashley Mortenson; Nadja B Cech
Journal:  Food Chem Toxicol       Date:  2007-06-15       Impact factor: 6.023

8.  Carbene generation by cytochromes and electronic structure of heme-iron-porphyrin-carbene complex: a quantum chemical study.

Authors:  Nikhil Taxak; Bhargav Patel; Prasad V Bharatam
Journal:  Inorg Chem       Date:  2013-04-05       Impact factor: 5.165

9.  In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products.

Authors:  B C Foster; S Vandenhoek; J Hana; A Krantis; M H Akhtar; M Bryan; J W Budzinski; A Ramputh; J T Arnason
Journal:  Phytomedicine       Date:  2003-05       Impact factor: 5.340

10.  Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.

Authors:  J Yang; W M Atkins; N Isoherranen; M F Paine; K E Thummel
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

View more
  5 in total

1.  Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions.

Authors:  Mary F Paine
Journal:  Drug Metab Dispos       Date:  2020-08-13       Impact factor: 3.922

2.  Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail.

Authors:  James T Nguyen; Dan-Dan Tian; Rakshit S Tanna; Deena L Hadi; Sumit Bansal; Justina C Calamia; Christopher M Arian; Laura M Shireman; Bálint Molnár; Miklós Horváth; Joshua J Kellogg; Matthew E Layton; John R White; Nadja B Cech; Richard D Boyce; Jashvant D Unadkat; Kenneth E Thummel; Mary F Paine
Journal:  Clin Pharmacol Ther       Date:  2020-12-23       Impact factor: 6.875

Review 3.  Modeling Pharmacokinetic Natural Product-Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach.

Authors:  Emily J Cox; Dan-Dan Tian; John D Clarke; Allan E Rettie; Jashvant D Unadkat; Kenneth E Thummel; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

4.  Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2022-01-20       Impact factor: 2.953

5.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.